ACHE and Alzheimer disease: Furthermore, bis(7)tacrine is an antagonist of the γ- aminobutyric acid type A (GABAA) receptor, having an IC50 of 6.28 μM. This observation leads to the inference that AChEIs with considerable GABAA receptor antagonism would be more effective for treating AD than simple AChE inhibition alone [7].